ArticleClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
THR as a Novel Biomarker for Carotid Stenosis Severity in Acute Ischemic Stroke: Implications for Risk Stratification and Personalized Management.
Article in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundThis study aims to investigate the role of the total cholesterol to high-density lipoprotein cholesterol ratio (THR) in predicting carotid stenosis in patients with acute ischemic stroke (AIS), aiming to establish its clinical utility in risk assessment and therapeutic decision-making.Methods180 patients with AIS and concomitant carotid stenosis were classified into three groups (classified as mild [<50%], moderate [50-70%], or severe [≥70%]) based on stenosis severity. These groups were compared to 180 healthy controls. Carotid stenosis was diagnosed in all participants using digital subtraction angiography, with the severity graded accordingly. THR and lipid profiles were analyzed within 24 h of admission. Statistical analyses included ANOVA, ROC curve evaluation, and multivariate regression to determine THR's predictive performance for stenosis severity.ResultsTHR levels were significantly elevated in AIS patients versus controls (3.80 ± 1.07 vs 3.02 ± 0.67; p < 0.05) and correlated with stenosis severity (mild: 3.22 ± 0.85; moderate:3.86 ± 0.91; severe: 4.33 ± 1.16; p < 0.05). ROC analysis demonstrated robust diagnostic accuracy (AUC: 0.807; 95% CI: 0.744-0.870), with a cutoff of 4.15 yielding 81.1% sensitivity and 95.6% specificity for severe stenosis.ConclusionsTHR is a cost-effective, independent biomarker for carotid stenosis severity in AIS; its clinical use improves risk stratification and guides personalized care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.